Merrimack Pharmaceuticals

From WikiMD's WELLNESSPEDIA

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. The company is primarily focused on the discovery, development, and commercialization of innovative medicines to treat cancer and improve the lives of patients suffering from cancer.

History[edit]

Merrimack Pharmaceuticals was founded in 2000 by a group of scientists from Massachusetts Institute of Technology (MIT). The company was established with the aim of integrating systems biology, bioengineering, and computational modeling to design novel therapeutics for cancer treatment.

Research and Development[edit]

Merrimack Pharmaceuticals has a robust Research and Development program. The company's R&D efforts are centered on understanding the complex biological processes that drive cancer growth and resistance to treatment. Merrimack uses this knowledge to develop innovative therapies that can disrupt these processes and improve patient outcomes.

Products[edit]

Merrimack's lead product, Onivyde, is approved in the United States and Europe for the treatment of metastatic pancreatic cancer. Onivyde is a novel encapsulation of the chemotherapy drug irinotecan, designed to increase the drug's effectiveness and reduce its side effects.

Financials[edit]

As a publicly traded company, Merrimack Pharmaceuticals is subject to financial reporting requirements. The company's financial performance is closely watched by investors and analysts in the biopharmaceutical industry.

See Also[edit]



This biopharmaceutical related article is a stub. You can help WikiMD by expanding it.

Stub icon

This oncology article is a stub. You can help WikiMD by expanding the page.

Stub icon

This corporation or company article is a stub. You can help WikiMD by expanding the page.


  • Logo of Merrimack Pharmaceuticals
    Logo of Merrimack Pharmaceuticals

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Merrimack_Pharmaceuticals&oldid=6495616"